**Aspirin to Prevent Cardiovascular Disease (CVD) and Colorectal Cancer (CRC):**

The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Age limit 50 to 59 years (men and women)</td>
</tr>
<tr>
<td>• No prior authorization</td>
</tr>
<tr>
<td>• Quantity limit of 100 units per fill</td>
</tr>
<tr>
<td>• Generic only</td>
</tr>
<tr>
<td>• Over the counter (OTC) (requires prescription)</td>
</tr>
</tbody>
</table>

**Generic Product Identifier (GPI) Description***

Single ingredient: All oral dosage forms 81 mg

Includes dosage forms such as:

• Aspirin chew tab 81 mg
• Aspirin enteric coated tab 81 mg

---

*Products listed may be updated periodically. ‡For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark.

©2019 CVS Caremark. All rights reserved. 106-21204G 062819
# Aspirin (cont.)

<table>
<thead>
<tr>
<th>Aspirin to Prevent Morbidity and Mortality From Preeclampsia: Women</th>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>The USPSTF recommends the use of low-dose aspirin (81 mg/day) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia.</td>
<td>• Females or members capable of pregnancy</td>
</tr>
<tr>
<td>• Age limit 12 to 59 years</td>
<td></td>
</tr>
<tr>
<td>• No prior authorization</td>
<td></td>
</tr>
<tr>
<td>• Quantity limit of 100 units per fill</td>
<td></td>
</tr>
<tr>
<td>• Generic only</td>
<td></td>
</tr>
<tr>
<td>• OTC (requires prescription)</td>
<td></td>
</tr>
</tbody>
</table>

**GPI Description**

**Single ingredient: All oral dosage forms 81 mg**

- Aspirin chew tab 81 mg
- Aspirin enteric coated tab 81 mg

---

# Oral Fluorides

<table>
<thead>
<tr>
<th>Chemoprevention of Dental Caries (Cavities)</th>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation at currently recommended doses to preschool children older than six months of age whose primary water source is deficient in fluoride.</td>
<td>• Age limit ≤ five years</td>
</tr>
<tr>
<td>• No prior authorization</td>
<td></td>
</tr>
<tr>
<td>• No quantity limit</td>
<td></td>
</tr>
<tr>
<td>• Brand and generic</td>
<td></td>
</tr>
<tr>
<td>• Rx products only</td>
<td></td>
</tr>
</tbody>
</table>

**GPI Description**

**Single ingredient: Oral dosage forms ≤ 0.5 mg**

- Sodium fluoride chew tab 0.25 mg - 0.5 mg
- Sodium fluoride soln 0.125 mg/drop & 0.25 mg/drop
- Sodium fluoride soln 0.25 mg/0.6 mL
- Sodium fluoride soln 0.5 mg/mL
- Sodium fluoride tab 0.5 mg

---

# Folic Acid

<table>
<thead>
<tr>
<th>Supplementation with Folic Acid</th>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>The USPSTF recommends that all women planning or capable of pregnancy take a daily supplement containing 0.4 mg to 0.8 mg (400 mcg to 800 mcg) of folic acid.</td>
<td>• Females or members capable of pregnancy</td>
</tr>
<tr>
<td>• Age limit ≤ 55</td>
<td></td>
</tr>
<tr>
<td>• No prior authorization</td>
<td></td>
</tr>
<tr>
<td>• Quantity limit 100 units per fill</td>
<td></td>
</tr>
<tr>
<td>• Generic only</td>
<td></td>
</tr>
<tr>
<td>• OTC (requires prescription)</td>
<td></td>
</tr>
</tbody>
</table>

**GPI Description**

**Single ingredient**

- Folic acid tab 0.4 mg & 0.8 mg
- Folic acid cap 0.8 mg

---

*Products listed may be updated periodically. ‡For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark.

©2019 CVS Caremark. All rights reserved. 106-21204G 062819
### Tobacco Cessation

**Adults who are not pregnant:**
The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration (FDA)–approved pharmacotherapy for cessation to adults who use tobacco.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No prior authorization of tobacco cessation products</td>
<td>- Bupropion HCl tab SR 12hr 150 mg</td>
</tr>
<tr>
<td>- Limit of 168 day supply of each product in one year of treatment</td>
<td>- Nicotine TD patch 24 hr 21 mg, 14 mg &amp; 7 mg/24hr</td>
</tr>
<tr>
<td>- Coverage includes generic nicotine replacement products (nicotine patch, gum and lozenges), brand Nicotrol (inhaler system), brand Nicotrol NS (nasal spray), brand Chantix and generic Zyban</td>
<td>- Nicotine polacrilex gum 2 mg &amp; 4 mg</td>
</tr>
<tr>
<td></td>
<td>- Nicotine polacrilex lozenge 2 mg &amp; 4 mg</td>
</tr>
<tr>
<td></td>
<td>- Nicotine inhaler system 10 mg (4 mg delivered)</td>
</tr>
<tr>
<td></td>
<td>- Nicotrol brand</td>
</tr>
<tr>
<td></td>
<td>- Nicotine nasal spray 10 mg/mL (0.5 mg/spray)</td>
</tr>
<tr>
<td></td>
<td>- Nicotrol NS brand</td>
</tr>
<tr>
<td></td>
<td>- Varenicline tartrate tab 0.5 mg (base equiv) &amp; 1 mg (base equiv)</td>
</tr>
<tr>
<td></td>
<td>- Chantix brand</td>
</tr>
<tr>
<td></td>
<td>- Varenicline tartrate tab 0.5 mg X 11 tabs &amp; 1 mg X 42 pack</td>
</tr>
<tr>
<td></td>
<td>- Chantix brand</td>
</tr>
</tbody>
</table>

*Products listed may be updated periodically. ‡For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark.

©2019 CVS Caremark. All rights reserved. 106-21204G 062819
**Immunizations**

**Immunizations: Vaccines**
The USPSTF recommends immunizations for routine use in children, adolescents and adults that are recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) on the CDC Immunization Schedules.

**CVS Caremark Recommendation**
- Children – birth through age 18
- Adults – covered age ≥ 19
- Rx only
- Plans may choose to cover vaccines under the medical or pharmacy benefit
- If plans cover under the pharmacy benefit any vaccines which appear on the Immunization Schedules of the CDC, then the non-grandfathered or new start plans should apply $0 copay for these vaccines‡

http://www.cdc.gov/mmwr/preview/mmwrhtml/su6201a1.htm
- No prior authorization

**Children:**
- Diphtheria, Tetanus, Pertussis
- Haemophilus Influenzae Type B
- Hepatitis A
- Hepatitis B
- Human Papillomavirus
- Inactivated Poliovirus
- Influenza
- Measles, Mumps, Rubella
- Meningococcal
- Pneumococcal
- Rotavirus
- Varicella

**Adults:**
Immunization vaccines for adults. Doses, recommended ages and recommended populations vary:
- Hepatitis A
- Hepatitis B
- Herpes Zoster
- Human Papillomavirus
- Influenza
- Measles, Mumps, Rubella
- Meningococcal
- Pneumococcal
- Tetanus, Diphtheria, Pertussis
- Varicella

*Products listed may be updated periodically. ‡For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark.

©2019 CVS Caremark. All rights reserved. 106-21204G 062819
### Bowel Preparation Medications

#### Screening for Colorectal Cancer
The USPSTF recommends screening for colorectal cancer (CRC) using fecal occult blood testing, sigmoidoscopy or colonoscopy, in adults, beginning at age 50 years and continuing until age 75 years.

Since colonoscopy is an option for screening, and adequate bowel preparation is required prior to the procedure, coverage of medications that will provide adequate preparation should be provided.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Age limit 50 through 74 years (men and women)</td>
</tr>
<tr>
<td>- No prior authorization or quantity limits</td>
</tr>
<tr>
<td>- Rx only</td>
</tr>
<tr>
<td>- Generics and single source brands</td>
</tr>
<tr>
<td>- Generics are in <em>italics</em>. Brand-names are <strong>CAPITALIZED</strong></td>
</tr>
<tr>
<td>- Brands until generics become available</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>- CLENPIQ</td>
</tr>
<tr>
<td>- MOVIPREP</td>
</tr>
<tr>
<td>- PLENVU</td>
</tr>
<tr>
<td>- PREPOPIK</td>
</tr>
<tr>
<td>- SUPREP</td>
</tr>
<tr>
<td>- Gavilyte-H Kit</td>
</tr>
<tr>
<td>- Peg-Prep Kit</td>
</tr>
</tbody>
</table>

### Statins

#### Statin Use for the Primary Prevention of Cardiovascular Disease (CVD) in Adults:
The USPSTF recommends that adults without a history of CVD (ie, symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the prevention of CVD events and mortality when all of the following criteria are met: 1) they are aged 40 to 75 years; 2) they have 1 or more CVD risk factors (ie, dyslipidemia, diabetes, hypertension, or smoking); and 3) they have a calculated 10-year risk of a cardiovascular event of 10% or greater.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Age limit 40 to 75 years (men and women)</td>
</tr>
<tr>
<td>- No prior authorization</td>
</tr>
<tr>
<td>- No quantity limit</td>
</tr>
<tr>
<td>- Generic only</td>
</tr>
<tr>
<td>- Only low to moderate intensity statins</td>
</tr>
<tr>
<td>- Rx</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic low to moderate intensity statins- includes the following strengths:</td>
</tr>
<tr>
<td>- Atorvastatin 10 mg, 20 mg</td>
</tr>
<tr>
<td>- Fluvastatin 20 mg, 40 mg</td>
</tr>
<tr>
<td>- Fluvastatin ER 80 mg</td>
</tr>
<tr>
<td>- Lovastatin 10 mg, 20 mg, 40 mg</td>
</tr>
<tr>
<td>- Pravastatin 10 mg, 20 mg, 40 mg, 80 mg</td>
</tr>
<tr>
<td>- Rosuvastatin 5 mg, 10 mg</td>
</tr>
<tr>
<td>- Simvastatin 5 mg, 10 mg, 20 mg, 40 mg</td>
</tr>
</tbody>
</table>
WOMEN’S PREVENTIVE SERVICES:
Interim Final Rules for Non-Grandfathered Group Health Plans and Health Insurance Issuers Coverage of Preventive Services under the Patient Protection and Affordable Care Act

Introduction
On August 1, 2011, the Department of Health and Human Services (HHS) adopted Guidelines for Women’s Preventive Services – including well-woman visits, support for breast feeding equipment, contraception and domestic violence screening – that will be covered without cost sharing in non-grandfathered health plan years starting on or after August 1, 2012. The guidelines were recommended by the independent Institute of Medicine (IOM) and based on scientific evidence.

<table>
<thead>
<tr>
<th>Oral Contraceptives</th>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The IOM Recommended as a Preventive Service for Women:</strong></td>
<td>• Females or members capable of pregnancy</td>
</tr>
<tr>
<td>The full range of U.S. Food and Drug Administration (FDA)-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.</td>
<td>• Rx</td>
</tr>
<tr>
<td>CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing its coverage under these provisions.</td>
<td>• Generics and single source brands</td>
</tr>
<tr>
<td>CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.</td>
<td>• Brands until generics become available</td>
</tr>
<tr>
<td>These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.</td>
<td></td>
</tr>
</tbody>
</table>

1. Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

<table>
<thead>
<tr>
<th>Product Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand names in <em>italics</em> and in parentheses are for reference only. Only generics and single source brands are recommended for coverage without cost sharing. Brand names in <em>(BOLD/BLUE)</em> have no generic available and are recommended for coverage. EE=Ethynyl Estradiol</td>
</tr>
</tbody>
</table>

**HIGH – DOSE MONOPHASIC PILLS**
- EE 50 mcg/Norgestrel 0.5 mg *(Ogestrel 0.5/50)*
- EE 50 mcg/Ethynodiol diacetate 1 mg *(Ethynodiol 1/50, Kelnor 1/50)*

**BIPHASIC PILLS**
- EE 20 mcg/Desogestrel 0.15 mg *(Azurette, Bekyree, Kariva, Mircette, Pimtrea, Simliya, Viorele)*

---

*Products listed may be updated periodically. ‡For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark.

©2019 CVS Caremark. All rights reserved. 106-21204G 062819
### Oral Contraceptives (cont.)

#### LOW-DOSE MONOPHASIC PILLS

- **EE 20 mcg/Drospirenone 3 mg**  
  (Gianvi, Jasmiel, Loryna, Nikki, Yaz)
- **EE 20 mcg/Drospirenone 3 mg + Calcium 0.451 mg (Beyaz)**
- **EE 20 mcg/Levonorgestrel 0.1 mg**  
  (Aubra, Aubra EQ, Aviane-28, Delyla, Falmina, Larissia, Lessina, Lutera, Orsythia, Sronyx, Vienva)
- **BALCOLTRA**  
  (EE 20 mcg/Levonorgestrel 0.1 mg/FE)
- **EE 20 mcg/Norethindrone 1 mg and FE**  
- **EE 20 mcg/Norethindrone 1 mg/FE**  
  (Melodetta 24 FE, Mibelas 24 FE, Minastrin 24 FE)
- **TAYTULLA FE 1/20**  
  (EE 20 mcg/Norethindrone 1 mg/FE)
- **EE 25 mcg/Norethindrone 0.8 mg/FE**  
  (Generess FE, Kaitlib FE, Layolis FE)
- **EE 30 mcg/Levonorgestrel 0.15 mcg**  
  (Altavera, Chateal, Chateal EQ, Kurvelo, Levora, Lillow, Marlissia, Portia-28)
- **EE 30 mcg/Norgestrel 0.03 mg**  
  (Crystals-28, Elinest, Low-Ogestrel)
- **EE 30 mcg/Norethindrone acetate 1.5 mg and/FE**  
  (Aurovela 1.5/30, Blisovi FE 1.5/30, Junel 1.5/30, Junel FE 1.5/30, Larin 1.5/30, Loestrin 1.5/30-21, Loestrin FE 1.5/30, Microgestin 1.5/30, Microgestin FE 1.5/30)
- **EE 30 mcg/Desogestrel 0.15 mg**  
  (Apri, Cyred, Cyred EQ, Enmoquette, Enskyce, Isibloom, Juleber, Reclipsen)
- **EE 30 mcg/Drospirenone 3 mg**  
  (Ocella, Syeda, Yasmin, Zarah)
- **EE 35 mcg/Ethinylodiol diacetate 1 mg**  
  (Kelnor 1/35, Zovia 1/35E)
- **EE 35 mcg/Norgestimate 0.25 mg**  
  (Estaryla, Femynor, Mili, Mono-linyah, Mononessa, Ortho-Cyclen, Previ fem, Sprin teco, Vylb ra)
- **EE 35 mcg/Norethindrone 0.4 mg and/FE**  
  (Balziva-28, Brielllyn, Philith, Vyfemla, Wymzya FE)
- **EE 35 mcg/Norethindrone 0.5 mg**  
  (Necon 0.5/35, Nortrel 0.5/35, Wera)
- **EE 35 mcg/Norethindrone 1 mg**  
  (Alyacen 1/35, Cyclafem 1/35, Dasetta 1/35, Nortrel 1/35, Ortho-Novum 1/35, Pirmella 1/35)
- **EE 30 mcg/Drospirenone 3 mg + Calcium 0.451 mg**  
  (Safyral, Tydemy)
<table>
<thead>
<tr>
<th>Oral Contraceptives (cont.)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TRIPHASIC PILLS</strong></td>
</tr>
</tbody>
</table>
| • EE 20 mcg, 30 mcg, 35 mcg/Norethindrone 1 mg  
  (*Estrostep FE, Tilia Fe, Tri-Legest FE*) |
| • EE 25 mcg/Norgestimate 0.18 mg, 0.215 mg, 0.25 mg  
  (*Ortho Tri-Cyclen Lo, Tri-Lo Estarylla, Tri-Lo Marzia, Tri-Lo Sprintec, Tri-Vylibra Lo*) |
| • EE 25 mcg/Desogestrel 0.1 mg, 0.125, 0.15 mg  
  (*Caziant, Velivet*) |
| • EE 30 mcg, 40 mcg, 30 mcg /Levonorgestrel 0.05 mg, 0.075 mg, 0.125 mg  
  (*Enpresse, Levonest, Trivora*) |
| • EE 35 mcg/Norgestimate 0.18 mg, 0.215 mg, 0.25 mg  
  (*Ortho Tri-Cyclen, Tri-Estarylla, Tri-Femynor, Tri-Linyah, Tri-Mili, TriNessa, Tri-Previfem, Tri-Sprintec, Tri-Vylibra*) |
| • EE 35 mcg/Norethindrone 0.5 mg, 1 mg, 0.5 mg  
  (*Aranelle, Leena, Tri-Norinyl*) |
| • EE 35 mcg/Norethindrone 0.5 mg, 0.75 mg, 1 mg  
  (*Alyacen 7/7/7, Cyclafem 7/7/7, Dasetta 7/7/7, Nortrel 7/7/7, Ortho-Novum 7/7/7, Pirmella 7/7/7*) |
| **FOUR-PHASIC**            |
| • **NATAZIA**              |
  *(Estradiol valerate/Dienogest)* |
| **EXTENDED – CYCLE PILLS** |
| • EE 30 mcg/Levonorgestrel 0.15 mg  
  (*Introvale, Jolessa, Setlakin*) |
| • EE 30, 10 mcg/Levonorgestrel 0.15 mg  
  (*Amethia, Ashlyna, Camrese, Daysee, Seasonique*) |
| • EE 20, 10 mcg/Levonorgestrel 0.1 mg  
  (*Amethia Lo, Camrese Lo, LoSeasonique*) |
| • **LO LOESTRIN FE**       |
  *(EE 10 mcg/Norethindrone 1 mg)* |
| • EE 10, 20, 25, 30 mcg/Levonorgestrel 0.15 mg  
  (*Fayosim, Quartette, Rivelsa*) |
| **CONTINUOUS – CYCLE PILLS** |
| • EE 20 mcg/Levonorgestrel 90 mcg  
  (*Amethyst*) |
| **PROGESTIN-ONLY PILLS “Mini-Pills”** |
| • Norethindrone 0.35 mg  
  (*Camila, Deblitane, Errin, Heather, Incassia, Jencycla, Jolivette, Lyza, Nora-BE, Norlyda, Norlyroc, Ortho Micronor, Sharobel, Tulana*) |
## Emergency Contraceptives

**The IOM Recommended as a Preventive Service for Women:**
The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.¹

CVS Caremark suggests a plan consider the following pharmacy-related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

1. Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

### CVS Caremark Recommendation
- Females or members capable of pregnancy
- Rx
- OTCs (requires a prescription)

### Product Description*
Brand names in *italics* and in parentheses are for reference only. Only generics and single source brands are recommended for coverage without cost-sharing. Brand names in **(BOLD/BLUE)** have no generic available and are recommended for coverage.

- **ELLA**
  (Ulipristal 30 mg tablet) (progesterone receptor modulator)
- Levonorgestrel 1.5 mg tablet
  (*Aftera, Plan B, Econtra EZ, Econtra OS, My Choice, My Way, New Day, Opicon, Option 2, Preventeza, Take Action, React*)

---

*Products listed may be updated periodically. ‡For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark.*

©2019 CVS Caremark. All rights reserved. 106-21204G 062819
## Injectables

<table>
<thead>
<tr>
<th>The IOM Recommended as a Preventive Service for Women:</th>
</tr>
</thead>
<tbody>
<tr>
<td>The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.¹</td>
</tr>
</tbody>
</table>

CVS Caremark suggests a plan consider the following pharmacy-related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

1. Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Females or members capable of pregnancy</td>
</tr>
<tr>
<td>- Quantity limit</td>
</tr>
<tr>
<td>(1 injection/75 days) or (4 injections/300 days)</td>
</tr>
<tr>
<td>- Rx</td>
</tr>
<tr>
<td>- Brands until generics become available</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand names in <em>italics</em> and in parenthesis are for reference only. Only generics and single source brands are recommended for coverage without cost sharing. Brand names in <em>(BOLD/BLUE)</em> have no generic available and are recommended for coverage.</td>
</tr>
</tbody>
</table>

- **DEPO-SUBQ-PROVERA 104**
  (Medroxyprogesterone acetate 104 mg SQ X q3 months)
- Medroxyprogesterone acetate 150 mg IM x q3 months *(Depo-Provera)*

---

*Products listed may be updated periodically. ¹For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark.

©2019 CVS Caremark. All rights reserved. 106-21204G 062819
## Miscellaneous – Intrauterine Devices, Subdermal Rods & Vaginal Rings

### The IOM Recommended as a Preventive Service for Women:

The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.  

CVS Caremark suggests a plan consider the following pharmacy-related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

1. Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

### CVS Caremark Recommendation

- Females or members capable of pregnancy
- Rx
- Plans may choose to cover these items under the medical or pharmacy benefit
- Quantity Limits
  - Sub-dermal Rod (1/300 days)
  - Intrauterine Device (IUD) (1/300 days)
  - Vaginal Ring (13/300 days)

### Product Description*

Brand names in *italics* and in parentheses are for reference only. Only generics and single source brands are recommended for coverage without cost sharing. Brand names in *(BOLD/BLUE)* have no generic available and are recommended for coverage.

- **NEXPLANON** Subdermal Rod  
  (Etonogestrel 68 mg – release rate varies over time)
- **MIRENA** IUD  
  (Levonorgestrel 20 mcg/day)
- **NUVARING** Vaginal Ring  
  (Ethinyl estradiol 15 mcg/Etonogestrel 120 mcg)
- **PARAGARD T 380A** IUD  
  (Copper 309 mg/day)
- **SKYLA** IUD  
  (Levonorgestrel 13.5 mcg/day)
- **LILETTA** IUD  
  (Levonorgestrel 18.6 mcg/day)
- **KYLEENA** IUD  
  (Levonorgestrel 19.5 mcg/day)

---

*Products listed may be updated periodically. ‡For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark. ©2019 CVS Caremark. All rights reserved. 106-21204G 062819*
**Transdermal Patch**

<table>
<thead>
<tr>
<th>The IOM Recommended as a Preventive Service for Women:</th>
</tr>
</thead>
<tbody>
<tr>
<td>The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.¹</td>
</tr>
</tbody>
</table>

CVS Caremark suggests a plan consider the following pharmacy-related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

1. Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Females or members capable of pregnancy</td>
</tr>
<tr>
<td>• Rx</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand names in <em>italics</em> and in parentheses are for reference only. Only generics and single source brands are recommended for coverage without cost sharing. Brand names in <em>(BOLD/BLUE)</em> have no generic available and are recommended for coverage.</td>
</tr>
<tr>
<td>• Ethinyl estradiol 35 mcg/Norelgestromin 150 mcg <em>(Xulane)</em></td>
</tr>
</tbody>
</table>

*Products listed may be updated periodically. ‡For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark. ©2019 CVS Caremark. All rights reserved. 106-21204G 062819
### Barrier Methods

#### The IOM Recommended as a Preventive Service for Women:

The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.¹

CVS Caremark suggests a plan consider the following pharmacy-related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

1. Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

#### CVS Caremark Recommendation

- Females or members capable of pregnancy
- Quantity Limit (1/300 days)
- Rx

#### Product Description*

Brand names in *italics* and in parentheses are for reference only. Only generics and single source brands are recommended for coverage without cost sharing. Brand names in *(BOLD/BLUE)* have no generic available and are recommended for coverage.

- Diaphragms
  - MILEX WIDE-SEAL
  - OMNIFLEX COIL SPRING SILICONE
  - CAYA
- Cervical Caps
  - FEMCAP

---

*Products listed may be updated periodically. **For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark. ©2019 CVS Caremark. All rights reserved. 106-21204G 062819*
OTC - Contraceptives

The IOM Recommended as a Preventive Service for Women:
The full range of FDA-approved contraceptive methods, sterilization procedures, and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.¹

CVS Caremark suggests a plan consider the following pharmacy-related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

¹. Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

CVS Caremark Recommendation
- Females or members capable of pregnancy
- OTC (requires prescription)

Product Description*
Brand names in *italics* and in parentheses are for reference only. Only generics and single source brands are recommended for coverage without cost sharing. Brand names in *(BOLD/BLUE)* have no generic available and are recommended for coverage.

- Female Condoms
- FC-2
- Vaginal Sponge
- TODAY (Nonoxynol-9)
- Spermicides
- Nonoxynol-9 Gel 4% (Conceptrol Gel 4%, VCF Vaginal Contraceptive Gel)
- ENCARE VAGINAL SUPPOSITORIES
- GYNOL II GEL 3%
- SHUR-SEAL GEL 2%
- VCF VAGINAL FILM 28%
- VCF VAGINAL FOAM 12.5%

Primary Prevention of Breast Cancer

Medications for Risk Reduction of Primary Breast Cancer in Women:
The USPSTF recommends that clinicians engage in shared, informed decision-making with women who are at increased risk for breast cancer, about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxifene.

CVS Caremark Recommendation
- Females or members at increased risk of breast cancer
- Age limit ≥ 35
- No prior authorization²
- Generic only
- Rx

². May be subject to certification process.

GPI Description*
- Raloxifene HCl tab 60 mg
- Tamoxifen citrate tab 10 mg (base equiv) & 20 mg (base equiv)
**OPTIONAL PREVENTIVE SERVICE:**
Medication-Assisted Treatment (MAT) for Substance Use Disorder

**Introduction**
Medication Assisted Treatment of Substance Use Disorder – or MAT – is an important tool to help reduce opioid misuse. MAT medications, including buprenorphine, buprenorphine-naloxone and naltrexone, are used in the treatment of opioid use disorders. In an effort to enhance access to MAT, CVS Caremark recommends coverage of three medications used in MAT as an optional preventive service, to be available at no member cost share.

<table>
<thead>
<tr>
<th>Optional MAT for Substance Use Disorder:</th>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
</table>
| In April 2017, the Department of Health and Human Services (HHS) detailed a five-point opioid strategy. A key tenet of their strategy was to “Improve access to prevention, treatment, and recovery support services to prevent the health, social, and economic consequences associated with opioid addiction and to enable individuals to achieve long-term recovery.” | • Generic only  
• Rx  
• In order to enhance access:  
  o No prior authorization  
  o No quantity limits

3. Client specific utilization management may apply |

<table>
<thead>
<tr>
<th>Generic Product Identifier (GPI) Description*</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Buprenorphine sublingual tab 2 mg, 8 mg</td>
<td></td>
</tr>
<tr>
<td>• Buprenorphine-naloxone sublingual tab 2 mg-0.5 mg, 8 mg-2 mg</td>
<td></td>
</tr>
<tr>
<td>• Naltrexone tab 50 mg</td>
<td></td>
</tr>
</tbody>
</table>

While MAT for Substance Use Disorder is not a required preventive service for ACA non-grandfathered plans, CVS Caremark recommends coverage of these drugs at no member cost share as a benefit enhancement.

*Products listed may be updated periodically. ‡For a complete listing of product names, contact your account representative. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements. This document contains proprietary information and may not be copied (in whole or in part), reproduced or distributed without written permission from CVS Caremark.
©2019 CVS Caremark. All rights reserved. 106-21204G 062819